Cambridge, Mass.-based Unum Therapeutics Inc. priced its IPO of 5,770,000 shares at $12 apiece.

The IPO is expected to close by April 3 with Morgan Stanley and Cowen acting as joint book-running managers and SunTrust Robinson Humphrey and Wedbush PacGrow acting as lead managers.

The biotechnology company granted underwriters an option to purchase up to an additional 865,500 shares.

The company's stock will start trading on the Nasdaq Global Select Market under the ticker symbol UMRX on March 29.